Testimony of Allan Coukell, Director of the Pew Prescription Project, on Protecting Consumers from Adulterated Drugs

Testimony of Allan Coukell, Director of the Pew Prescription Project, on Protecting Consumers from Adulterated Drugs

Thank you for the opportunity to present comments and to participate today in this important discussion. My name is Allan Coukell. I am a pharmacist and director of the Pew Prescription Project – an initiative established by The Pew Charitable Trusts to represent consumer interests on a range of drug safety issues, including the risk of adulterated medicines.

Protecting consumers against the risk of adulterated products is, of course, the original mission of the FDA.1 Today, the vast majority of pharmaceutical products sold in the United States today are not adulterated, but an increasingly complex supply chain creates new challenges and new risks – as recent events demonstrate.

Economically motivated adulteration includes the potential for contaminated, sub-potent or counterfeit medication to enter the supply chain at several levels, from the production of raw ingredients through to the point of retail sale.

The true prevalence of such adulteration is unknown. The severity of reactions associated with heparin in 2007 and 2008 made it likely that the contamination would be detected, albeit too late. However, a less toxic contaminant or an inert or sub-potent formulation would be more likely to escape notice.

In recent years, the pharmaceutical supply chain has become increasingly complex, extending beyond our shores in unprecedented ways. By one widely-cited 1998 estimate, nearly 80% of all active pharmaceutical ingredients now originate outside the United States, a trend that can only have increased in the past decade.2 Americans now consume pharmaceuticals that originate in thousands of manufacturing facilities in developing nations outside the formal jurisdiction of FDA.

Even an adulteration rate of less than 1 percent, could equate to millions of American consumers exposed each year.3

To protect the supply chain, regulatory activity occurs at multiple levels:

  • Promulgation of good manufacturing practices and related standards
  • Compliance reviews, including inspections of manufacturing facilities
  • Review of pharmaceutical imports at the point of entry to the United States
  • Oversight of pharmaceutical distribution within the United States

Download the PDF to read the complete testimony from Alan Coukell.

1 Created through the Food and Drugs Act of 1906.
2 U.S. Government Accountability Office. (2007, November). Drug Safety: Preliminary Findings Suggest Weakness in FDA's Program for Inspecting Foreign Drug Manufacturers. (Publication No. GAO-08-224T)
3 An estimate by FDA officials of the prevalence of counterfeit drugs in the US – one specific kind of economically motivated adulteration. Rudolph, PM and Bernstein, IBG. “Counterfeit Drugs” N Engl J Med. April 1, 2004. Vol. 350: 1384-1386

Downloads PDF Download
Downloads PDF Download

Spotlight on Mental Health

Composite image of modern city network communication concept

Learn the Basics of Broadband from Our Limited Series

Sign up for our four-week email course on Broadband Basics

Quick View

How does broadband internet reach our homes, phones, and tablets? What kind of infrastructure connects us all together? What are the major barriers to broadband access for American communities?

Pills illustration
Pills illustration

What Is Antibiotic Resistance—and How Can We Fight It?

Sign up for our four-week email series The Race Against Resistance.

Quick View

Antibiotic-resistant bacteria, also known as “superbugs,” are a major threat to modern medicine. But how does resistance work, and what can we do to slow the spread? Read personal stories, expert accounts, and more for the answers to those questions in our four-week email series: Slowing Superbugs.

Explore Pew’s new and improved
Fiscal 50 interactive

Your state's stats are more accessible than ever with our new and improved Fiscal 50 interactive:

  • Maps, trends, and customizable charts
  • 50-state rankings
  • Analysis of what it all means
  • Shareable graphics and downloadable data
  • Proven fiscal policy strategies


Welcome to the new Fiscal 50

Key changes include:

  • State pages that help you keep track of trends in your home state and provide national and regional context.
  • Interactive indicator pages with highly customizable and shareable data visualizations.
  • A Budget Threads feature that offers Pew’s read on the latest state fiscal news.

Learn more about the new and improved Fiscal 50.